Jun. 1 at 4:53 PM
eXoZymes (Nasdaq:
$EXOZ ) details how its cell-free platform produces the enzyme function data that powers AI-driven biomanufacturing.
eXoZymes Inc. (Nasdaq: EXOZ) shared a video in which Tyler Korman, PhD, Co-founder and VP of Research, explains why AI is well suited to enzyme engineering and why the company’s ability to generate unique enzyme function data may set its cell-free platform apart.
eXoZymes is a B2i Digital Featured Company. See the company’s profile at b2idigital.com/exozymes-1.
In the video, Korman explains that AI is fundamentally a question of data. He compares the 20 amino acids that build proteins to the letters of an alphabet, where the same building blocks can be arranged into millions of proteins and enzymes, each with a different function. The obstacle, he notes, has been the readout: AI can predict what a protein’s letters and structure might look like, but the function itself often remains unknown.
eXoZymes is focused on closing that gap by measuring enzyme function directly, generating the data its models learn from. By making targeted changes to amino acids and observing the effect on function, the team can design, build, and test enzymes without first passing sequences through an organism or conducting sequencing, which helps shorten the work of generating and screening enzyme libraries. Looking further out, Korman points to linking enzyme steps into cascades of reactions, coupling biological pathways to move from low-cost inputs to nutraceuticals, pharmaceuticals, and specialty chemicals more efficiently. As Korman put it, the ability to generate this function data is “where some of our secret power lies,” helping eXoZymes refine its models and continue learning with large language models.
Watch the video: https://exozymes.com/blog/exoz-ai-part1
Learn more at https://exozymes.com and about other B2i Digital Featured Companies at https://b2idigital.com/featured-companies.
Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.
$DNLI,
$TWST,
$DNA,
$ARKG